Archives

by in
Entry Author Date Location
10 Takeaways From New York’s Life Science Disruptors 03/10/14 New York
Supreme Court Should Scale Back Securities Class Actions 03/04/14 National
East Coast Biotech Roundup: HART, CoStim, Forest/Actavis, & More 02/21/14 Boston
East Coast Biotech Roundup: ASH, Proteostasis, Retrophin, & More 12/13/13 Boston
Hologic Names New CEO, Cuts Deal With Icahn to Avoid Proxy Fight 12/09/13 Boston
Hologic, Fending off Icahn, Adopts Poison Pill to Deflect Takeover 11/21/13 Boston
Boston Roundup: CoachUp, Clypd, Terrafugia, Nuance 11/21/13 Boston
Icahn Withdraws Opposition to Dell Buyback Offer 09/10/13 Texas
Buyout Battle Highlights Dell’s History, Role in Austin Startup Scene 08/02/13 Texas
Boston Tech Roundup: Attune, Cognex, GreenBytes, LevelUp, & More 04/04/13 Boston
Enzon, under Pressure from Carl Icahn, Seeks Buyer 12/17/12 New York
SD Life Sciences Roundup: Amylin, Illumina, AstraZeneca Acquires Ardea, & More 04/27/12 San Diego
How Biogen Idec Overhauled R&D Under Doug Williams 03/07/12 Boston
George Scangos, the Boy From Working Class Boston, on His Road Back to Lead Biogen Idec 08/31/11 Boston
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent 07/18/11 National
Dendreon Faces Internet-Fueled Shareholder Uprising, Led by a Little Guy in Kansas 04/01/11 Seattle
Biogen Idec Nabs Doug Williams as R&D Head, Steve Holtzman as BD Chief To Fill Out Management Team 01/05/11 Boston
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan 11/04/10 Boston
5 Biotech Storylines to Watch in Boston 10/13/10 Boston
Motricity’s Ryan Wuerch on the Post-IPO Game Plan, International Expansion, and the New Wave of Mobile 10/08/10 Seattle
Genzyme Boss Henri Termeer Not Ready To Sell to Sanofi, Ride Into the Sunset, Sources Say 09/22/10 Boston
Genzyme Agrees to Sell Genetics Unit to LabCorp for $925M 09/13/10 Boston
Susan Windham-Bannister on the State of the State’s $1B Life Sciences Initiative, Part II 08/18/10 Boston
Susan Windham-Bannister on the State of the State’s $1B Life Sciences Initiative, Part I 08/17/10 Boston
Xconomy Readers Set $20B Pricetag on Genzyme—Is That Too Rich for Sanofi-Aventis? 07/29/10 Boston
Genzyme Stock Surges 15 Percent on Sanofi Buyout Speculation 07/23/10 Boston
New CEO George Scangos Says Biogen Idec’s R&D Has to Improve 07/01/10 Boston
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO 06/30/10 Boston
Motricity Completes IPO, Settles For $50M 06/18/10 Seattle
Curis Misses Mark in Cancer Drug Trial, Genzyme Re-Elects Full Board, GTC Cuts Jobs, & More Boston-Area Life Sciences News 06/18/10 Boston
Page 1 of 6 next page »